Therapy Area

Subcutaneous drugs grant a new lease on life to checkpoint inhibitors

The PD-1/PD-L1 inhibitor landscape is at the precipice of change with the approval of Roche’s subcutaneous formulation of Tecentriq.

Cardiovascular

View More

Central Nervous System

View More

Immunology

View More

Infectious Disease

View More

Oncology

View More

Respiratory

View More